logo
Share SHARE
FONT-SIZE Plus   Neg

Zalicus To Halt Further Clinical Development With Synavive - Quick Facts

Zalicus Inc. (ZLCS) announced the results from its randomized, double-blind, placebo-controlled, Phase 2b clinical trial of Synavive in rheumatoid arthritis or RA. The company said that in the absence of a clinically meaningful benefit with Synavive compared to its active glucocorticoid component, it will discontinue further clinical development with Synavive.

The company said that Phase 2b trial demonstrated that patients treated with Synavive achieved a statistically significant improvement in signs and symptoms of moderate to severe RA compared to placebo, as measured by Disease Activity Score (DAS28-CRP), after 12 weeks of treatment, which represents a -0.9 change from baseline for Synavive (about 17% improvement) compared to a -0.5 change from baseline for placebo (about 10% improvement), but missed the key secondary endpoint of demonstrating a meaningful clinical benefit, assessed by DAS28-CRP, compared to prednisolone 2.7mg, the active glucocorticoid component in Synavive.

"Going forward we will focus our resources and efforts on advancing the clinical development of our ion channel programs including Z160, our first-in-class treatment for neuropathic pain which recently advanced into the first of two Phase 2a clinical trials, and Z944, our novel, oral, T-type calcium channel blocker which is completing multiple Phase 1 studies and if successful will advance into Phase 2 development in the first half of 2013." said Mark H.N. Corrigan, MD, CEO of Zalicus.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Food delivery startup DoorDash and courier service Postmates have joined with robotic delivery developer Starship Technologies for conducting commercial delivery trials over the next few weeks. With Starship's self-driving delivery robots, DoorDash will do the delivery tests in Redwood City, California, while Postmates' tests will take place in Washington, D.C. They will carry food orders ... Aiming to better prepare its employees, Delta Air Lines has decided to begin new diversity training for all of its flight crews after incidents of alleged discrimination against passengers, Bloomberg reported. *** is the stock in focus, on the merit of its valuation and upbeat guidance revision. The company ***, a vendor of fiber-optic components, revised up fourth-quarter revenue guidance above Street estimates. We think the stock has at least 10% upside from current levels.
comments powered by Disqus
Follow RTT